Introduction

The intersection of traditional medicine and food regulation in India has created a complex legal landscape where jurisdictional boundaries remain contentious. The creation of a separate Ministry of AYUSH (Ayurveda, Yoga & Naturopathy, Unani, Siddha and Homoeopathy) in 2014 alongside the established Food Safety and Standards Authority of India (FSSAI) has given rise to significant jurisdictional conflicts regarding products that bridge the gap between traditional medicinal preparations and food supplements. These jurisdictional disputes directly impact thousands of manufacturers, affecting product formulation, licensing requirements, marketing claims, and ultimately consumer access. This article examines the legal dimensions of these jurisdictional conflicts, exploring the regulatory frameworks, key areas of contention, attempted resolutions, and their market impact.

Legal Framework Governing Dual Jurisdiction

The dual regulation of medicinal foods and supplements stems from two separate legislative frameworks with distinct historical origins. The Food Safety and Standards Act, 2006 established the FSSAI as the apex food regulatory body in India, consolidating various food laws that had previously been administered by different ministries. Section 16 of this Act empowers FSSAI to regulate and monitor the manufacture, distribution, sale, and import of food to ensure safety and quality, including items that may have health benefits. This broad mandate naturally encompasses traditional food products with health claims, including those with roots in Ayurvedic and other traditional medicinal systems.

Concurrently, the Drugs and Cosmetics Act, 1940, and its subsequent amendments provide the regulatory framework for traditional medicines, including Ayurvedic, Siddha, and Unani (ASU) products. The Ministry of AYUSH, established as a separate ministry in 2014 (previously a department within the Ministry of Health and Family Welfare), administers this Act for traditional medicine systems. Under Sections 33A to 33O of this Act, the manufacturing, labeling, and sale of ASU drugs are regulated, with licensing powers vested with state licensing authorities.

This dual regulatory framework creates inherent jurisdictional overlaps, particularly for products that could reasonably be classified as either foods with medicinal properties or medicines consumed as foods. The legal complexity increased with the notification of Food Safety and Standards (Ayurveda Aahara) Regulations, 2022, which created a specialized category within the FSSAI framework for food products based on Ayurvedic texts, requiring collaboration between FSSAI and the Ministry of AYUSH.

Key Areas of Jurisdictional Conflicts Between FSSAI and Ayush

Product classification represents the most significant area of jurisdictional conflicts between FSSAI and the AYUSH Ministry. The legal distinction between a food supplement and an Ayurvedic medicine often hinges on interpretive factors rather than clear statutory boundaries. This classification dilemma was highlighted in a 2021 case involving Patanjali Ayurved, where the company challenged FSSAI’s classification of certain herbal products as food supplements requiring FSSAI licensing rather than as Ayurvedic medicines under AYUSH regulation. The Delhi High Court’s interim ruling emphasized the need for clearer classification criteria while allowing the products to continue selling under existing licenses pending final resolution.

Manufacturing license requirements create another layer of jurisdictional conflict. Until recently, manufacturers had to maintain separate facilities for producing FSSAI-licensed products and AYUSH-regulated medicines, significantly increasing compliance costs. On August 31, 2023, the Ministry of AYUSH issued a clarification stating that “there is no specific prohibition to use combined setup of manufacturing line and equipment for manufacturing products licensed under Ayurveda, Siddha, and Unani, and FSSAI.” This clarification resolved one aspect of the jurisdictional conflict but underscored the ongoing need for regulatory coordination.

The legal framework for labeling and health claims represents another contentious area. FSSAI regulations prohibit disease-prevention or therapeutic claims on food products, while AYUSH regulations permit such claims for registered Ayurvedic medicines based on references in classical texts. This creates a legal dichotomy where identical ingredients might face different claim restrictions depending on their regulatory classification. The ambiguity was partially addressed in May 2024 when the AYUSH Ministry explicitly warned manufacturers against claiming “nutraceutical value” for AYUSH drugs, emphasizing that they fall under different regulatory categories than FSSAI-regulated nutraceuticals.

Regulatory Convergence Efforts

Recognizing the challenges posed by jurisdictional conflicts between FSSAI and AYUSH in the regulation of overlapping products, both bodies have initiated formal convergence efforts. A significant milestone was the formation of a joint committee in 2022, comprising experts from both FSSAI and the AYUSH Ministry, to establish harmonized standards and approval processes for products caught in this regulatory overlap. This committee was given the mandate to provide recommendations on approval of claims and products while addressing concerns regarding registration, licensing, certification, laboratory accreditation, testing, and quality issues related to Ayurveda Aahara.

The most substantial regulatory convergence came with the notification of the Food Safety and Standards (Ayurveda Aahara) Regulations, 2022. These regulations created a specialized category—”Ayurveda Aahara”—defined as “food prepared in accordance with the recipes or ingredients or processes as per methods described in the authoritative books of Ayurveda listed under Schedule A of the Drugs and Cosmetics Act.” This definition officially recognized a category of products at the intersection of food and Ayurvedic medicine, with a special logo to distinguish them in the marketplace. Section 5 of these regulations explicitly established that FSSAI would constitute an expert committee under the Ministry of AYUSH for evaluating these products, creating a formal collaborative framework.

Another convergence milestone was the AYUSH Ministry’s February 2020 announcement of collaboration with FSSAI for a new food regulation framework based on Ayurveda, acknowledging that many traditional food items evolved from kitchen practices rather than formal pharmaceutical processes. This conceptual shift recognized that many traditional preparations might be better regulated as foods with health-promoting properties rather than as medicines.

Market Impact and Compliance Challenges

The jurisdictional ambiguities have created significant market challenges, particularly regarding labeling compliance and permissible claims. In May 2024, the AYUSH Ministry issued a directive specifically prohibiting AYUSH products from claiming “nutraceutical value,” emphasizing that such terminology belongs to the FSSAI regulatory domain. This directive highlighted the ongoing effort to establish clearer boundaries between the two regulatory spaces while acknowledging their inevitable overlap.

The risk of enforcement actions against products making unauthorized claims creates substantial legal uncertainty for manufacturers. FSSAI has been particularly active in monitoring and penalizing misleading claims, with numerous enforcement actions against products making disease-prevention claims without proper authorization. In one notable case, FSSAI took action against a manufacturer marketing products with Ayurvedic ingredients but making claims that crossed into therapeutic territory without proper AYUSH authorization, imposing penalties under Section 53 of the FSS Act for misleading advertisements.

Consumer protection concerns further complicate the regulatory landscape. Both regulatory frameworks emphasize consumer safety, but their differing approaches to evidence requirements create potential gaps. FSSAI generally requires scientific evidence for health claims, while AYUSH permits claims based on references in classical texts. This difference in evidentiary standards creates a potential legal loophole where manufacturers might seek the less stringent pathway for bringing products to market.

Legal Liability Distribution

The question of legal liability distribution in this dual regulatory environment remains particularly complex. Under Section 27 of the FSS Act, liability for food safety violations extends to manufacturers, distributors, and sellers. Similarly, the Drugs and Cosmetics Act imposes liability on manufacturers and sellers of medicines that violate standards or make false claims. However, when a product falls into the regulatory gray area between these frameworks, determining the applicable liability provisions becomes challenging.

The Food Safety and Standards (Ayurveda Aahara) Regulations, 2022 partially addressed this issue by explicitly stating that these products must comply with FSSAI’s food safety standards while meeting the ingredient and formulation requirements of Ayurvedic texts. This creates a hybrid liability framework where both sets of safety requirements must be satisfied, but enforcement authority remains divided.

For manufacturers, this often results in a defensive strategy of seeking dual licensing—obtaining both FSSAI approval and AYUSH licensing—to minimize liability risks. This approach, while legally prudent, increases compliance costs and administrative burdens. Small and medium enterprises particularly struggle with navigating these complex requirements, potentially limiting innovation in traditional products with health benefits.

Enforcement authority also remains a contentious issue. Food Safety Officers appointed under the FSS Act and Drug Inspectors appointed under the Drugs and Cosmetics Act have overlapping inspection powers for products in the gray area. This can lead to conflicting enforcement actions, with manufacturers potentially facing penalties from both authorities for the same violation, raising questions of double jeopardy and proportionate enforcement.

Conclusion and Future Outlook

The jurisdictional conflicts between FSSAI and the AYUSH Ministry regarding medicinal foods and supplements reflect the challenges of integrating traditional knowledge systems into modern regulatory frameworks. While significant strides have been made toward regulatory convergence, particularly through the Ayurveda Aahara regulations, substantial legal ambiguities remain. These conflicts directly impact manufacturers’ ability to innovate and bring traditional products to market, potentially limiting consumer access to beneficial traditional preparations.

Moving forward, further regulatory harmonization will be essential. This may require legislative amendments to more clearly delineate jurisdiction based on product characteristics rather than historical regulatory divisions. Additionally, establishing unified inspection and enforcement protocols for products in the overlapping space could reduce compliance burdens while maintaining necessary safety standards.

The ongoing dialogue between the two regulatory bodies represents a positive development, acknowledging that the traditional separation between food and medicine categories may not adequately reflect the holistic approach of traditional Indian medical systems. As this regulatory landscape continues to evolve, manufacturers and legal practitioners must stay vigilant to changes in both frameworks while advocating for greater clarity and consistency in regulations governing these unique products.

References

1. Food Safety and Standards Act, 2006, No. 34, Acts of Parliament, 2006 (India).
2. Drugs and Cosmetics Act, 1940, No. 23, Acts of Parliament, 1940 (India).
3. Food Safety and Standards (Ayurveda Aahara) Regulations, 2022, Gazette of India, Part III, Sec. 4 (India).
4. Ministry of AYUSH. (2023, August 31). Clarification regarding manufacturing of FSSAI licensed products in AYUSH approved facilities. F. No. L.4012/04/2023.
5. Ministry of AYUSH. (2024, May 1). Directive on nutraceutical value claims for AYUSH products. Circular No. Z.28015/32/2024-DCC.
6. Patanjali Ayurved v. Food Safety and Standards Authority of India, Delhi High Court, Writ Petition (Civil) No. 7688 of 2021.
7. Food Safety and Standards Authority of India. (2020, February 17). Memorandum of Understanding between FSSAI and Ministry of AYUSH for regulation of Ayurveda Aahara. F. No. RCD-01/34/2020.
8. Manorama Yearbook. (2022, May 14). AYUSH ministry, FSSAI formulate regulations for ‘Ayurveda Aahara’ products.
9. NutraIngredients-Asia. (2023, September 13). FSSAI-licensed products could be made in AYUSH-approved facilities.
10. Corpseed. (2023, October 31). Difference Between FSSAI License and Ayush License. 

The post Jurisdictional Conflicts Between FSSAI and Ayush Ministry Regarding Medicinal Foods and Supplements appeared first on Bhatt & Joshi Associates.

Introduction

Medicinal plants hold a profound significance in the healthcare systems of India, blending ancient traditions with contemporary pharmaceutical innovations. Their prominence in Ayurveda, Siddha, Unani, and modern medicine underscores their value as both cultural artifacts and economic assets. However, the rising global demand for herbal remedies and pharmaceutical derivatives has presented both opportunities and challenges. These include issues of overharvesting, habitat degradation, and unsustainable trade practices, which necessitate a well-structured regulatory framework and active governance. The National Medicinal Plants Board (NMPB) serves as the cornerstone of this regulatory framework in India, promoting the sustainable cultivation, conservation, and utilization of medicinal plants.

This article explores the multifaceted role of medicinal plants in India, the establishment and functioning of the NMPB, the regulatory mechanisms governing the sector, significant judicial interventions, and the challenges and opportunities shaping the future of medicinal plants.

Historical and Cultural Relevance of Medicinal Plants in India

India has a rich heritage of traditional medicine, with ancient texts like the Charaka Samhita and Sushruta Samhita documenting the use of medicinal plants for therapeutic purposes. These plants formed the bedrock of traditional healthcare systems, providing remedies for ailments ranging from common colds to chronic diseases. The use of these plants transcends mere medicinal purposes, integrating into the spiritual and cultural practices of Indian society.

The global recognition of traditional Indian medicine, fueled by increasing interest in Ayurveda and herbal therapies, has further elevated the status of medicinal plants. However, this recognition has brought challenges, including the overexploitation of natural resources, loss of biodiversity, and questions surrounding the intellectual property rights of traditional knowledge holders.

Establishment and Objectives of the National Medicinal Plants Board

Recognizing the critical need to conserve medicinal plants and ensure their sustainable utilization, the Government of India established the National Medicinal Plants Board (NMPB) in 2000 under the Ministry of AYUSH. The NMPB serves as a nodal agency for coordinating all matters related to medicinal plants, focusing on conservation, cultivation, trade promotion, and integration into healthcare systems.

Objectives of the NMPB

1. Conservation of Medicinal Plants: To ensure that medicinal plants, especially endangered and rare species, are preserved through in-situ and ex-situ conservation methods.
2. Promotion of Cultivation: To reduce dependency on wild resources by encouraging large-scale cultivation of medicinal plants.
3. Market and Trade Development: To streamline the supply chain and facilitate market access for cultivators and traders.
4. Research and Development: To support scientific studies that validate the efficacy and safety of medicinal plants, integrating traditional knowledge with modern science.
5. Awareness and Capacity Building: To educate stakeholders, including farmers, researchers, and healthcare providers, about the sustainable use of medicinal plants.

The NMPB implements its objectives through various schemes, such as the Central Sector Scheme on Conservation, Development, and Sustainable Management of Medicinal Plants and initiatives under the National AYUSH Mission.

Regulatory Framework Governing Medicinal Plants in India

The regulation of medicinal plants in India is a complex interplay of conservation laws, trade policies, and quality standards. Several key legislations form the backbone of this framework:

Biological Diversity Act, 2002

This act is a cornerstone of India’s biodiversity conservation efforts. It provides a framework for sustainable use and equitable benefit-sharing of biological resources, including medicinal plants. The act established the National Biodiversity Authority (NBA) to regulate access to genetic resources and prevent bio-piracy.

The NBA collaborates with the NMPB to ensure that the extraction and trade of medicinal plants do not harm biodiversity or exploit traditional knowledge holders. For instance, permissions are required for accessing bio-resources for commercial purposes, and benefit-sharing agreements must be negotiated with local communities.

Forest Conservation Act, 1980

Many medicinal plants grow in forest ecosystems, making the Forest Conservation Act crucial in regulating their harvest. The act prohibits the indiscriminate extraction of forest resources, mandating approval for non-forest activities in forest areas.

State forest departments often work with the NMPB to implement conservation projects and monitor the sustainable collection of medicinal plants from forests. This coordination ensures that biodiversity is not sacrificed for economic gains.

Drugs and Cosmetics Act, 1940

The Drugs and Cosmetics Act governs the manufacture, sale, and distribution of herbal drugs. It ensures that medicinal plants used in Ayurveda, Siddha, and Unani medicines meet prescribed quality standards. The NMPB collaborates with regulatory bodies to promote good manufacturing practices (GMP) and ensure the safety and efficacy of herbal formulations.

Wildlife Protection Act, 1972

Certain medicinal plants, such as sandalwood, are classified as protected species under the Wildlife Protection Act. The act imposes restrictions on their harvest and trade, with penalties for violations. This ensures that rare and endangered species are not overexploited.

Conservation and Cultivation Initiatives by the NMPB

In-Situ Conservation

In-situ conservation involves preserving medicinal plants in their natural habitats. The NMPB supports projects that establish Medicinal Plant Conservation Areas (MPCAs) in biodiversity-rich regions. These areas are protected from activities like deforestation and overharvesting, ensuring that native species thrive.

Ex-Situ Cultivation

To reduce pressure on wild resources, the NMPB promotes the cultivation of medicinal plants outside their natural habitats. Financial incentives and technical support are provided to farmers under schemes like the National AYUSH Mission. This approach not only conserves biodiversity but also provides economic opportunities for rural communities.

Community Participation

The NMPB emphasizes community involvement in conservation efforts. Local communities are encouraged to participate in the sustainable harvest of medicinal plants and share in the benefits derived from their use. This participatory approach aligns with the principles of the Biological Diversity Act.

Research and Development in Medicinal Plants

Research is a critical component of the NMPB’s mandate. The board funds studies to validate the therapeutic properties of medicinal plants, develop new formulations, and address challenges in cultivation and conservation. Collaborative research with institutions like the Indian Council of Agricultural Research (ICAR) and the Council of Scientific and Industrial Research (CSIR) enhances scientific understanding and promotes innovation.

For example, studies on plants like Ashwagandha (Withania somnifera) and Giloy (Tinospora cordifolia) have provided scientific validation for their traditional uses, boosting their acceptance in global markets.

Challenges in the Regulation of Medicinal Plants in India

Despite significant progress, several challenges hinder the effective regulation and sustainable use of medicinal plants:

Overexploitation and Habitat Loss 

The high demand for medicinal plants often leads to overharvesting, threatening the survival of species. Habitat destruction due to deforestation and urbanization exacerbates the problem, reducing the availability of wild resources.

Illegal Trade

The illegal trade of medicinal plants, driven by high market demand and weak enforcement, poses a significant challenge. Rare species are often smuggled out of the country, bypassing regulatory controls and depriving local communities of benefits.

Climate Change

Climate change affects the growth and distribution of medicinal plants, altering their chemical composition and efficacy. Adaptive measures are needed to mitigate these impacts and ensure the sustainability of medicinal plant resources.

Lack of Market Access

Farmers and small-scale cultivators often face difficulties in accessing markets due to inadequate infrastructure and knowledge about market dynamics. Strengthening market linkages and providing fair prices are essential for promoting the cultivation of medicinal plants.

Intellectual Property Issues

The commercialization of traditional knowledge raises concerns about bio-piracy and the equitable sharing of benefits. Strengthening intellectual property protections and benefit-sharing mechanisms is crucial to addressing these issues.

Judicial Interventions in Medicinal Plant Conservation

Indian courts have played a pivotal role in addressing issues related to medicinal plant conservation and sustainable use. Landmark judgments have underscored the importance of balancing economic interests with ecological sustainability.

In T.N. Godavarman Thirumulpad v. Union of India (1996), the Supreme Court highlighted the need for strict implementation of forest conservation laws, directly impacting the regulation of medicinal plants. The judgment led to the establishment of the Forest Advisory Committee, which evaluates proposals for non-forest activities.

In Centre for Environmental Law v. Union of India (2013), the Supreme Court directed authorities to implement conservation strategies for endangered medicinal plants. The judgment emphasized the responsibility of the state to protect biodiversity under the Biological Diversity Act.

International Frameworks and India’s Commitment

India’s regulatory efforts align with international agreements such as the Convention on Biological Diversity (CBD) and the Nagoya Protocol. These frameworks promote sustainable use, conservation, and equitable benefit-sharing of biological resources.

The Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) regulates the international trade of medicinal plants. The NMPB works closely with the Ministry of Environment, Forest, and Climate Change to ensure compliance with CITES provisions.

Opportunities and the Future of Medicinal Plants

The increasing global demand for herbal products presents significant opportunities for India to become a leader in the medicinal plant industry. To realize this potential, the NMPB must address existing challenges and leverage technological innovations.

Digital tools such as GIS mapping and blockchain can enhance traceability and transparency in the supply chain. Collaborations with global organizations can boost research and market access, ensuring that India’s medicinal plants are recognized for their quality and efficacy.

Conclusion: Securing the Future of Medicinal Plants in India

Medicinal plants are an invaluable resource for healthcare, livelihoods, and cultural heritage. The National Medicinal Plants Board, through its proactive initiatives and regulatory oversight, has made substantial progress in promoting their sustainable use and conservation. However, addressing challenges like habitat loss, illegal trade, and market barriers requires concerted efforts from all stakeholders.

By integrating traditional knowledge with modern science and aligning national policies with international frameworks, India can secure its position as a global leader in

the medicinal plant sector. The NMPB’s role will remain pivotal in ensuring that the benefits of medicinal plants are realized equitably and sustainably, contributing to the health and economic well-being of future generations.

The post Medicinal Plants in India: Comprehensive Overview of the National Medicinal Plants Board and Regulatory Framework appeared first on Bhatt & Joshi Associates.

Introduction

India’s rich heritage of traditional medicine systems forms an integral part of its healthcare landscape. The regulation of Ayurveda, Yoga, Unani, Siddha, and Homoeopathy (collectively known as AYUSH) is primarily overseen by two statutory bodies: the Central Council of Indian Medicine (CCIM) and the Central Council of Homoeopathy (CCH). These councils operate under the Ministry of AYUSH, Government of India, and play a crucial role in preserving, promoting, and regulating these ancient healing traditions while ensuring their integration into the modern healthcare system.

Historical Context and Evolution of AYUSH

The journey of regulating traditional medicine in India is as old as the systems themselves, with each having its own historical methods of ensuring quality and standards. However, the modern regulatory framework for these systems began to take shape in the post-independence era.

In the years following India’s independence, there was a growing recognition of the need to preserve and promote traditional medicine systems. This led to the establishment of the Central Council of Indian Medicine (CCIM) in 1971 under the Indian Medicine Central Council Act, 1970. The CCIM was tasked with regulating the education and practice of Ayurveda, Siddha, and Unani systems of medicine.

Similarly, recognizing the growing popularity and distinct nature of Homoeopathy, the Central Council of Homoeopathy (CCH) was established in 1973 under the Homoeopathy Central Council Act, 1973. This council was given the mandate to regulate homoeopathic education and practice in India.

The regulation of Yoga and Naturopathy has a slightly different trajectory. While these systems are part of the AYUSH framework, they do not have a separate statutory regulatory body. Instead, their regulation is overseen by the Ministry of AYUSH in conjunction with various governmental and non-governmental organizations.

A significant milestone in the evolution of AYUSH regulation was the establishment of the Department of Indian Systems of Medicine and Homoeopathy (ISM&H) in 1995, which was later renamed as the Department of AYUSH in 2003. This department was elevated to the status of a full-fledged ministry in 2014, marking the government’s commitment to the promotion and development of traditional medicine systems.

Organizational Structure and Functions

The Central Council of Indian Medicine (CCIM) and the Central Council of Homoeopathy (CCH) have similar organizational structures, reflecting their parallel roles in regulating different systems of traditional medicine.

The CCIM consists of members elected from among practitioners of Ayurveda, Siddha, and Unani medicine, as well as representatives from each state and union territory. It also includes members nominated by the central government, representing various stakeholders in the field of traditional medicine.

Similarly, the CCH comprises elected members from among registered homoeopathic practitioners, representatives from state boards, and nominees of the central government. Both councils have a President and Vice-President elected from among their members.

The primary functions of these councils include:

1. Prescribing minimum standards of education in AYUSH systems: This involves setting curricula, determining the duration of courses, and specifying the skills and knowledge to be imparted to students.
2. Recognizing qualifications: The councils are responsible for recognizing medical qualifications granted by universities or medical institutions in India.
3. Registering practitioners: They maintain a Central Register of practitioners in their respective systems of medicine.
4. Regulating professional conduct: The councils lay down and enforce standards of professional conduct and etiquette for practitioners.
5. Advising the government: They provide recommendations to the central government on matters relating to the recognition of medical qualifications and the regulation of these traditional medicine systems.

Legislative Framework of AYUSH

The regulatory framework for AYUSH systems is primarily based on two key legislations:

1. The Indian Medicine Central Council Act, 1970: This Act provides for the constitution of the Central Council of Indian Medicine and the maintenance of a Central Register of Indian Medicine. It outlines the structure, functions, and powers of the CCIM.
2. The Homoeopathy Central Council Act, 1973: This Act establishes the Central Council of Homoeopathy and provides for the regulation of homoeopathic education and practice in India.

These Acts have been amended several times over the years to address emerging challenges and to strengthen the regulatory framework. For instance, the Indian Medicine Central Council (Amendment) Act, 2020, and the Homoeopathy Central Council (Amendment) Act, 2020, were passed to oversee the functioning of the respective councils and to ensure transparency and accountability in their operations.

In addition to these primary legislations, several other laws and regulations impact the AYUSH sector:

1. The Drugs and Cosmetics Act, 1940, and Rules 1945 (as amended): These provide for the regulation of AYUSH drugs, including their manufacture, sale, and distribution.
2. The Medicinal and Toilet Preparations (Excise Duties) Act, 1955: This Act deals with the levy and collection of duties of excise on medicinal and toilet preparations containing alcohol, opium, Indian hemp, or other narcotic drugs.
3. Biological Diversity Act, 2002: This Act is relevant to the AYUSH sector as it regulates access to biological resources, which form the basis of many traditional medicines.
4. The Scheduled Tribes and Other Traditional Forest Dwellers (Recognition of Forest Rights) Act, 2006: This Act has implications for the sourcing of medicinal plants used in traditional medicine systems.

Key Regulatory Processes and Mechanisms

The CCIM and CCH employ various regulatory processes and mechanisms to fulfill their mandates:

1. Curriculum Development: The councils regularly update and revise the curricula for AYUSH education to ensure they remain relevant and incorporate the latest developments in the field. This process involves consultation with experts, practitioners, and academicians.
2. Accreditation of Educational Institutions: Both CCIM and CCH are responsible for assessing and accrediting institutions offering courses in their respective systems of medicine. This involves regular inspections and evaluations of infrastructure, faculty, and teaching methods.
3. Standardization of Pharmacopoeias: The councils work in collaboration with the Pharmacopoeia Commission for Indian Medicine & Homoeopathy (PCIM&H) to develop and update pharmacopoeias for AYUSH medicines. This is crucial for ensuring the quality and standardization of traditional medicines.
4. Research Promotion: While not directly involved in research, the councils play a role in promoting and guiding research in AYUSH systems. They collaborate with research institutions and provide inputs on research priorities.
5. Continuing Medical Education: The councils organize and accredit continuing education programs for registered practitioners to ensure they stay updated with the latest developments in their fields.
6. Ethics and Disciplinary Mechanisms: Both CCIM and CCH have mechanisms in place to address ethical issues and professional misconduct among practitioners.

Recent Regulatory Developments and Initiatives

The AYUSH sector has seen several significant developments in recent years:

1. National Commission for Indian System of Medicine (NCISM) Act, 2020: This Act aims to replace the CCIM with a new commission, similar to the National Medical Commission for allopathic medicine. The NCISM is expected to bring about comprehensive reforms in the regulation of education and practice of Indian systems of medicine.
2. National Commission for Homoeopathy (NCH) Act, 2020: Similarly, this Act replaces the CCH with a new commission for homoeopathy. These new commissions are intended to ensure transparency, accountability, and quality in AYUSH education and practice.
3. Integration with Modern Medicine: There have been efforts to integrate AYUSH systems with modern medicine, particularly in primary healthcare. The National Medical Commission (NMC) has proposed modules on AYUSH systems for MBBS students, indicating a move towards a more integrated approach to healthcare.
4. AYUSH Grid Project: This initiative aims to digitize the AYUSH sector, creating a comprehensive IT backbone for all AYUSH systems. This includes digitizing health records, creating a central repository of AYUSH knowledge, and facilitating telemedicine in AYUSH.
5. Traditional Knowledge Digital Library (TKDL): This database documents traditional knowledge related to medicinal plants and formulations used in Indian systems of medicine. It serves as a tool to prevent misappropriation of traditional knowledge through wrongful patents.
6. Good Manufacturing Practices (GMP) for AYUSH Products: The Ministry of AYUSH has been working on enhancing the quality standards for AYUSH products through the implementation of Good Manufacturing Practices.

Challenges and Controversies of AYUSH System

The regulation of AYUSH systems faces several challenges and has been subject to various controversies:

1. Standardization and Quality Control: One of the biggest challenges is ensuring standardization and quality control of AYUSH medicines. The complexity and diversity of formulations, along with the use of natural ingredients, make this particularly challenging.
2. Evidence-Based Practice: There is ongoing debate about the need for evidence-based practices in AYUSH systems. While traditional knowledge is valued, there is increasing pressure to validate the efficacy of treatments through modern scientific methods.
3. Integration with Modern Medicine: The integration of AYUSH systems with modern medicine has been a contentious issue. While proponents argue for a holistic approach to healthcare, critics raise concerns about the scientific validity of some AYUSH practices.
4. Regulation of Practitioners: Ensuring that all AYUSH practitioners are properly qualified and registered remains a challenge, particularly in rural areas where traditional healers may practice without formal qualifications.
5. Intellectual Property Rights: The protection of traditional knowledge and prevention of biopiracy is an ongoing concern. The Biodiversity Act and initiatives like TKDL aim to address this, but challenges remain.
6. Cross-System Practice: The issue of AYUSH practitioners prescribing allopathic medicines and vice versa has been a subject of legal and ethical debates. The landmark case of Dr. Mukhtiar Chand & Ors. vs. State of Punjab & Ors. (1998) addressed this issue, but controversies persist.

International Collaborations and Global Standing

The regulation and promotion of AYUSH systems have significant international dimensions:

1. WHO Collaborations: India has been working closely with the World Health Organization (WHO) to develop benchmarks for training in Ayurveda, Yoga, and Unani. The WHO Global Centre for Traditional Medicine, set up in Gujarat, India, is a significant step towards global recognition of traditional medicine systems.
2. International Cooperation: The Ministry of AYUSH has signed Memorandums of Understanding (MoUs) with several countries for cooperation in traditional medicine. These agreements often include provisions for mutual recognition of qualifications and exchange of expertise.
3. AYUSH Mark: The government has introduced the AYUSH Premium Mark to certify quality AYUSH products for the international market, aiming to enhance the global acceptance of Indian traditional medicines.
4. Yoga Diplomacy: The international promotion of Yoga, including the establishment of International Yoga Day, has significantly enhanced the global profile of Indian traditional wellness practices.
5. Research Collaborations: There are increasing collaborations between Indian AYUSH institutions and international research organizations to conduct scientific studies on traditional medicines and practices.

Future Directions and Challenges

As AYUSH systems continue to gain prominence both nationally and internationally, several key areas will shape their future regulation and development:

1. Integration of Traditional and Modern Systems: The challenge lies in finding a balanced approach that respects the fundamental principles of AYUSH systems while leveraging modern scientific methods for validation and research.
2. Digitalization and Telemedicine: The AYUSH Grid and other digital initiatives are likely to play a crucial role in expanding the reach of AYUSH systems, particularly in remote areas.
3. Sustainable Sourcing of Medicinal Plants: As demand for AYUSH products grows, ensuring sustainable sourcing of medicinal plants will be crucial. This involves conservation efforts and promoting cultivation of medicinal plants.
4. Global Recognition and Standardization: Efforts towards gaining global recognition for AYUSH qualifications and practices are likely to intensify. This may involve further alignment with international standards and practices.
5. Research and Development: Enhancing research capabilities in AYUSH systems, including conducting large-scale clinical trials and publishing in reputed international journals, will be key to their wider acceptance.
6. Addressing Regulatory Gaps: The transition to the new regulatory bodies (NCISM and NCH) will need to address existing regulatory gaps and enhance the overall governance of AYUSH systems.
7. Capacity Building: There will be a continued focus on improving the quality of AYUSH education and enhancing the skills of practitioners to meet evolving healthcare needs.

Conclusion: The Future of AYUSH Regulation and Its Impact

The regulation of Ayurveda, Yoga, Unani, Siddha, and Homoeopathy in India represents a unique blend of preserving ancient wisdom while adapting to modern healthcare demands. The Central Council of Indian Medicine and the Central Council of Homoeopathy, along with their successor bodies, play a crucial role in this complex landscape.

As India continues to position itself as a global leader in traditional medicine, the regulatory framework for AYUSH systems will need to evolve to meet both domestic healthcare needs and international standards. The challenges are significant – from ensuring quality and efficacy to integrating with modern medical practices – but so are the opportunities.

The future of AYUSH regulation in India will likely see a continued emphasis on scientific validation, quality control, and global integration, while staying true to the fundamental principles of these traditional systems. As these ancient healing traditions meet modern regulatory standards and scientific scrutiny, they have the potential to contribute significantly to global healthcare solutions.

The journey of AYUSH regulation in India is more than just a regulatory exercise; it’s a reflection of India’s efforts to harness its rich cultural heritage to meet contemporary health challenges. As these systems continue to evolve and gain recognition, their regulation will play a crucial role in shaping the future of healthcare not just in India, but potentially around the world.

The post Ayurveda, Yoga, Unani, Siddha and Homoeopathy (AYUSH)- Central Council of Indian Medicine (CCIM) and Central Council of Homoeopathy (CCH) appeared first on Bhatt & Joshi Associates.

Introduction

Ayurveda and traditional medicine have long been integral to India’s rich cultural and medical heritage. This system, rooted in holistic healing, emphasizes the balance between mind, body, and spirit. Traditional medicine systems, including Ayurveda, Siddha, Unani, and others, have evolved over millennia and continue to hold relevance in the modern era, both in India and globally. As public interest in alternative and complementary medicine grows, understanding the legal framework that governs these systems becomes increasingly crucial. With the establishment of the Ministry of AYUSH and the development of regulatory laws, Ayurveda has achieved legal recognition in India. However, it also faces various regulatory challenges in quality control, commercialization, and global integration.

Historical Context of Ayurveda and Traditional Medicine

Ayurveda’s roots trace back over 3000 years to ancient Indian texts such as the Charaka Samhita and Sushruta Samhita, which outlined complex theories of healing based on natural elements, diet, lifestyle, and medicinal plants. Traditionally, medicine in India was closely aligned with religious and spiritual practices, forming an essential part of the Vedic way of life. As colonial influence introduced allopathic medicine, Ayurveda and other traditional systems faced marginalization. However, post-independence India saw a revival of interest in these systems as the government sought to reinstate indigenous knowledge alongside modern healthcare practices.

Efforts to institutionalize traditional medicine gained momentum during the mid-20th century, leading to the enactment of laws aimed at preserving and regulating Ayurveda, Siddha, Unani, and other systems. As globalization expanded Ayurveda’s reach, the legal status of traditional medicine became more nuanced, focusing on regulation, research, education, and international cooperation.

Legal Framework Governing Ayurveda and Traditional Medicine

India has developed an extensive legal framework that governs the practice, education, and commercialization of Ayurveda and other traditional medicine systems. The government established the Ministry of AYUSH in 2014 to formalize and regulate these practices. This was a crucial step in ensuring that Ayurveda, along with other traditional systems, would have legal backing, regulated practice, and enhanced public health benefits. The ministry oversees various laws and regulatory bodies, which ensure adherence to quality and safety standards.

The Indian Medicine Central Council Act, 1970  

A milestone in Ayurveda’s legal journey, this Act established the Central Council of Indian Medicine (CCIM). The CCIM is responsible for regulating educational standards and ensuring the professional competence of Ayurvedic, Unani, and Siddha practitioners. The Act also formalized the registration of practitioners, ensuring that only those with appropriate qualifications can practice Ayurveda. This was a crucial step in curbing the rise of unlicensed and potentially harmful practitioners while promoting Ayurveda as a credible and scientifically supported system of medicine.

The Drugs and Cosmetics Act, 1940 (AYUSH Amendments)  

As Ayurveda gained popularity in the post-independence era, concerns over the safety and efficacy of Ayurvedic drugs emerged. The Drugs and Cosmetics Act of 1940, amended to include Ayurvedic and Unani medicines, provides comprehensive regulations for the manufacture, sale, and distribution of Ayurvedic drugs. The act defines “Ayurvedic drugs” and outlines strict guidelines that ensure that medicines adhere to prescribed quality standards. The goal of these amendments was to maintain the integrity of Ayurvedic medicine while protecting consumers from substandard or adulterated products.

The National AYUSH Mission (2014)  

Recognizing the growing demand for alternative medicine, the National AYUSH Mission was launched to strengthen and promote Ayurveda and traditional medicine systems. This mission emphasized improving healthcare services and infrastructure, fostering educational institutions, and promoting research. One of the mission’s key elements was the development of quality control standards to ensure that Ayurvedic treatments were safe, effective, and accessible.

The National Commission for Indian System of Medicine (NCISM) Act, 2020  

Replacing the Indian Medicine Central Council Act, 1970, this Act established the National Commission for Indian System of Medicine (NCISM) to further elevate the standards of education and practice in Ayurveda, Unani, and Siddha. The NCISM is tasked with advancing research in traditional medicine, ensuring the uniformity of educational standards, and integrating these systems into the national healthcare framework. The Act reflects the government’s commitment to enhancing the credibility of Ayurveda by focusing on evidence-based practices and ensuring that practitioners are well-qualified.

Regulation of Ayurveda Practitioners and Education

The regulation of practitioners is a critical aspect of Ayurveda’s legal framework. Unqualified practitioners pose significant risks to public health, and strict guidelines are needed to ensure that only those with proper credentials can practice. Under the Indian Medicine Central Council Act, 1970, only practitioners registered with the Central Council of Indian Medicine (CCIM) were legally permitted to practice Ayurveda. However, with the introduction of the National Commission for Indian System of Medicine (NCISM) Act, 2020, the scope of regulation has expanded.

Ayurvedic education in India is heavily regulated, with institutions required to adhere to standards laid down by the NCISM. This regulation ensures that students receive comprehensive and rigorous training in both traditional Ayurvedic principles and modern scientific methods. The government has also taken steps to enhance research in Ayurveda, with initiatives aimed at integrating Ayurvedic medicine with contemporary medical research.

Drugs and Quality Control in Ayurveda and Traditional Medicine

The quality control of Ayurvedic drugs remains a critical challenge in the regulatory framework. As the demand for herbal supplements and Ayurvedic remedies increases, the need for rigorous standards becomes more pressing. The Ayurvedic Pharmacopoeia of India (API), published by the government, provides guidelines for the quality control of Ayurvedic medicines. This pharmacopoeia defines the composition of Ayurvedic formulations, ensuring that they are safe and meet certain efficacy standards.

The Drugs and Cosmetics Act, 1940, mandates that manufacturers of Ayurvedic medicines follow strict guidelines in preparing these medicines. However, the diverse nature of Ayurvedic formulations, which often rely on natural ingredients that vary based on environmental factors, poses unique challenges for standardization. Variations in soil, climate, and preparation methods can result in discrepancies in the potency and effectiveness of Ayurvedic medicines.

Insights on Ayurveda and Traditional Medicine

Indian courts have played a significant role in shaping the legal landscape of Ayurveda and traditional medicine. The judiciary has intervened to ensure that regulatory standards are upheld, protect consumers from malpractice, and preserve the integrity of traditional systems. Several landmark judgments have reinforced the importance of maintaining high standards in Ayurveda while respecting its historical and cultural significance.

One of the most notable cases in this context is Hamdard Dawakhana v Union of India (1960 AIR 554), where the Supreme Court addressed the issue of advertising Ayurvedic products. The court ruled that while traditional medicine systems must be promoted, public health should not be compromised by misleading advertisements. The case emphasized that Ayurvedic products must meet scientific standards and should not exploit consumers by making unfounded health claims.

In Smt. R. Nandhini v The State of Tamil Nadu (W.P. No. 10764 of 2017), the court addressed the issue of unlicensed Ayurvedic practitioners. The court ruled that only practitioners who are properly registered and qualified under the Indian Medicine Central Council Act or the NCISM Act could legally practice Ayurveda. This case highlights the judiciary’s role in ensuring that practitioners meet legal standards to protect patients from harm.

In K.L. Vaidya v Union of India (W.P. No. 1039/2015), the court dealt with the contentious issue of whether Ayurveda practitioners could prescribe allopathic medicines. The court ruled that Ayurveda practitioners are restricted to practicing within their domain and cannot prescribe modern medicines unless they hold qualifications in allopathy. This judgment reinforced the distinction between traditional and modern medicine, emphasizing that both systems must remain regulated in their respective fields.

Challenges in Regulating Ayurveda and Traditional Medicine

Despite significant strides in regulating Ayurveda, several challenges persist. One of the main issues is the quality control of Ayurvedic medicines. Unlike allopathic drugs, Ayurvedic formulations rely heavily on natural products, which vary in potency based on environmental conditions. Standardizing these formulations poses a significant challenge for regulatory authorities. Manufacturers often face difficulties ensuring consistency in their products, leading to concerns over safety and efficacy.

Another challenge is the commercialization of Ayurveda. With the rising global demand for Ayurvedic products, there is a growing risk of commercialization compromising quality. Unscrupulous manufacturers may prioritize profits over product integrity, leading to the sale of substandard or adulterated products. The government needs to enforce stricter penalties for manufacturers who fail to meet regulatory standards.

Furthermore, Ayurveda faces challenges in being integrated into mainstream healthcare. Although it enjoys legal recognition, it often remains on the periphery of India’s national healthcare system. Many patients choose Ayurveda as an alternative rather than a complementary system of treatment. There is a need for greater collaboration between allopathic and Ayurvedic practitioners to offer patients more comprehensive and integrated healthcare solutions.

Global Recognition of Ayurveda and Traditional Medicine

Ayurveda’s influence extends beyond India’s borders. In recent years, countries such as the United States, Germany, Australia, and Sri Lanka have embraced traditional medicine practices. Internationally, Ayurveda is recognized as a complementary and alternative medicine (CAM) under the World Health Organization’s (WHO) Traditional Medicine Strategy 2014-2023, which encourages the integration of traditional systems like Ayurveda into national healthcare policies.

In countries such as Sri Lanka, Ayurveda has been legally recognized as part of the national healthcare system through the Ayurveda Act. The United States recognizes Ayurveda as part of the complementary and alternative medicine spectrum, although it remains largely unregulated. Ayurveda practitioners in the U.S. face legal hurdles due to the lack of a standardized regulatory framework.

Integration of Ayurveda into Modern Healthcare

The integration of Ayurveda into modern healthcare remains an area of concern. While Ayurveda is legally recognized and regulated in India, its acceptance as a complementary system of medicine rather than an alternative system has not been fully realized. Modern medicine tends to dominate the healthcare landscape, often relegating traditional systems like Ayurveda to secondary status. However, several initiatives aim to bridge the gap between modern and traditional medicine.

One such initiative is the promotion of integrative medicine, where Ayurveda and modern allopathy are used in conjunction to treat patients. Integrative medicine combines the strengths of both systems—Ayurveda’s holistic approach and modern medicine’s precision and evidence-based methods. The Indian government has initiated several programs to promote this integrative approach, and there are now hospitals and clinics that offer treatments combining both Ayurveda and modern medicine.

For instance, All India Institute of Ayurveda (AIIA), established in Delhi, is a premier institution that promotes Ayurveda’s integration into the mainstream medical system. AIIA collaborates with modern healthcare professionals to conduct research and provide treatments that incorporate both Ayurvedic and allopathic practices. This model seeks to offer patients more holistic and personalized care, highlighting the potential of Ayurveda to complement, rather than compete with, modern medicine.

Research and Development in Ayurveda

One of the critical aspects of Ayurveda’s legal framework is its emphasis on research and development (R&D). The Indian government has encouraged extensive research to scientifically validate Ayurvedic practices and remedies. Research institutes such as the Central Council for Research in Ayurvedic Sciences (CCRAS) play a pivotal role in advancing the scientific understanding of Ayurveda. The CCRAS conducts clinical trials, undertakes research on medicinal plants, and publishes findings to create a solid evidence base for Ayurvedic treatments.

The establishment of the National Medicinal Plants Board (NMPB) under the Ministry of AYUSH is another step towards ensuring the sustainable use of medicinal plants. The NMPB focuses on promoting the cultivation and conservation of medicinal plants, which form the backbone of Ayurvedic treatments. This initiative addresses concerns about the depletion of natural resources and the potential environmental impact of large-scale harvesting of medicinal plants.

Furthermore, international collaboration in Ayurveda research is growing. Indian research institutions are partnering with global universities and healthcare organizations to conduct joint studies on Ayurvedic medicines and therapies. Such research not only strengthens Ayurveda’s credibility but also helps establish standards for its global practice.

Consumer Protection and Patient Safety in Ayurveda

While Ayurveda offers immense benefits, there is also a need for strong consumer protection measures to ensure patient safety. The Drugs and Cosmetics Act, 1940, and its amendments provide a regulatory framework for Ayurvedic drugs, but there are concerns about the enforcement of these regulations. The sheer diversity of Ayurvedic preparations, the use of natural ingredients, and the reliance on ancient formulations present unique challenges in ensuring consistency and safety.

One significant issue is the lack of rigorous clinical trials for many Ayurvedic medicines. While modern allopathic drugs undergo extensive testing before they are approved for public use, Ayurvedic medicines often rely on traditional knowledge and centuries-old practices. Although traditional wisdom is valuable, there is a growing demand for more scientific validation of these remedies. The Ministry of AYUSH has recognized this need and is working to encourage research that will provide a stronger scientific basis for Ayurvedic medicines.

In addition to drug regulation, there is also a need for better oversight of Ayurvedic practitioners. As noted earlier, only practitioners registered with regulatory bodies like the National Commission for Indian System of Medicine (NCISM) are legally permitted to practice Ayurveda. However, unqualified practitioners continue to operate in some areas, posing risks to public health. Stricter enforcement of laws regulating practitioners is necessary to protect patients from harmful practices.

Global Expansion and Challenges for Ayurveda

The global expansion of Ayurveda has been a double-edged sword. While Ayurveda is increasingly recognized as a valuable system of alternative medicine, it also faces legal and regulatory challenges in different parts of the world. In some countries, Ayurveda is classified as a form of complementary and alternative medicine (CAM), but it lacks the robust legal framework that modern medicine enjoys.

For example, in the United States, Ayurveda is practiced under the umbrella of CAM, but Ayurvedic practitioners often face legal challenges due to the lack of standardized certification or regulatory bodies. Ayurvedic medicines are subject to the same stringent regulations as dietary supplements, and manufacturers must comply with the U.S. Food and Drug Administration (FDA) standards for safety and efficacy. However, many Ayurvedic products are classified as herbal supplements rather than medicines, leading to a grey area in their regulation.

In the European Union, Ayurveda faces similar challenges. While some countries, like Germany, have embraced Ayurveda as part of their healthcare systems, others have yet to establish clear regulatory frameworks. Ayurvedic practitioners in these regions often struggle to obtain legal recognition, and Ayurvedic products are subject to various national and regional regulations. This lack of uniformity poses a significant barrier to the global growth of Ayurveda.

India, through its Ministry of AYUSH, has taken steps to address these challenges by promoting Ayurveda internationally. India has signed agreements with several countries to establish frameworks for recognizing Ayurvedic practitioners and regulating Ayurvedic medicines. For example, India has collaborated with the World Health Organization (WHO) to develop international standards for traditional medicine, including Ayurveda. These efforts aim to ensure that Ayurveda is recognized and regulated consistently across borders, allowing practitioners to operate legally and safely in different countries.

Ayurveda in the Post-Pandemic Era

The COVID-19 pandemic has renewed interest in traditional medicine, including Ayurveda. As people around the world seek natural and preventive healthcare solutions, Ayurveda’s emphasis on immunity, lifestyle changes, and natural remedies has resonated with many. During the pandemic, the Ministry of AYUSH actively promoted Ayurvedic practices and herbal formulations to boost immunity and reduce the risk of infection.

The pandemic also highlighted the importance of integrative medicine. In several cases, Ayurvedic treatments were used alongside allopathic care for COVID-19 patients, demonstrating the potential for these systems to work in tandem. While allopathic medicine remained the primary treatment for COVID-19, Ayurveda’s focus on preventive care and immune health gained significant traction. This renewed interest in traditional medicine presents both opportunities and challenges for the regulatory framework governing Ayurveda.

On one hand, the post-pandemic era offers a chance for Ayurveda to integrate more deeply into mainstream healthcare, both in India and globally. On the other hand, it also raises questions about the need for stricter quality control, research, and regulation to ensure that Ayurvedic treatments are both safe and effective. The surge in demand for herbal remedies during the pandemic has also highlighted the risks of commercialization and the potential for substandard products entering the market.

Conclusion 

Ayurveda and traditional medicine hold a unique legal and cultural status in India, and their influence is growing globally. The legal framework that governs Ayurveda, through the Ministry of AYUSH, the NCISM, and other regulatory bodies, has made significant strides in ensuring that traditional medicine is practiced safely and effectively. However, challenges remain in areas such as quality control, commercialization, global recognition, and integration with modern healthcare.

The judicial system has also played a vital role in shaping the legal landscape of Ayurveda, with key judgments reinforcing the need for regulatory oversight and protecting patients from malpractice. As Ayurveda continues to expand globally, India must continue to lead efforts to standardize and regulate traditional medicine, ensuring that it maintains its integrity while adapting to the needs of modern healthcare systems.

In conclusion, the future of Ayurveda depends on a careful balance between preserving its ancient wisdom and adapting to the demands of the modern world. With the right regulatory framework, research, and global cooperation, Ayurveda can continue to thrive as a vital part of both India’s cultural heritage and the world’s healthcare landscape.

The post The Legal Status of Ayurveda and Traditional Medicine: A Comprehensive Analysis appeared first on Bhatt & Joshi Associates.